• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

P-糖蛋白诱导作用的研究进展

许悦, 陈根富, 熊涛, 彭英, 阮婷婷, 王广基, 孙建国

许悦, 陈根富, 熊涛, 彭英, 阮婷婷, 王广基, 孙建国. P-糖蛋白诱导作用的研究进展[J]. 中国药科大学学报, 2018, 49(1): 26-33. DOI: 10.11665/j.issn.1000-5048.20180104
引用本文: 许悦, 陈根富, 熊涛, 彭英, 阮婷婷, 王广基, 孙建国. P-糖蛋白诱导作用的研究进展[J]. 中国药科大学学报, 2018, 49(1): 26-33. DOI: 10.11665/j.issn.1000-5048.20180104
shu
XU Yue, CHEN Genfu, XIONG Tao, PENG Ying, RUAN Tingting, WANG Guangji, SUN Jianguo. Research progress of P-glycoprotein induction[J]. Journal of China Pharmaceutical University, 2018, 49(1): 26-33. DOI: 10.11665/j.issn.1000-5048.20180104
Citation: XU Yue, CHEN Genfu, XIONG Tao, PENG Ying, RUAN Tingting, WANG Guangji, SUN Jianguo. Research progress of P-glycoprotein induction[J]. Journal of China Pharmaceutical University, 2018, 49(1): 26-33. DOI: 10.11665/j.issn.1000-5048.20180104
shu

P-糖蛋白诱导作用的研究进展

  • 1.

    中国药科大学药物代谢动力学重点实验室

  • 2.

    上海药明康德新药开发有限公司药性评价部

基金项目: 国家自然科学基金资助项目(No.81773987,No.81530098)；“重大新药创制”国家科技重大专项资助项目(No.2015ZX09501001,No.2017ZX09101001)

Research progress of P-glycoprotein induction

摘要

    摘要
  • 摘要: P-糖蛋白(P-gp)是ATP结合盒转运体家族中重要的外排转运体。诱导作用可上调细胞外排转运体的表达并增强其功能，从而减少外源性有害异物造成的伤害，对维持细胞内环境稳态有重要作用。本文结合课题组的研究，综述了近年来P-gp的诱导模型、实验方法及其在新药研究中的应用。重点总结了多种P-gp的体外细胞诱导模型和体内动物诱导模型，检测P-gp基因、蛋白表达水平和外排转运功能的实验方法，以及P-gp与代谢酶、其他转运体的共同调节作用。同时介绍了以P-gp诱导进行临床解毒治疗的策略以及计算机辅助设计的P-gp诱导药效基团模型。本综述为临床前药物设计、新合成化合物诱导活性的筛选和潜在临床药物相互作用的预测提供一定的指导。
    Abstract: P-glycoprotein(P-gp)is an important efflux protein of ATP-binding cassette transporter superfamily. Cells could be protected from detrimental xenobiotics by the up-regulation of efflux pumps. In this review, an extensive literature search for P-gp induction research was conducted, and a focus was brought onto the P-gp induction models, experiment methods and its applications in drug discovery. We mainly introduced the in vitro cell-based models and in vivo rodent animal models for induction research, methods that investigate induction potency by detecting the protein, gene expression and efflux function, as well as co-regulation between P-gp and other transporters or drug metabolism enzymes. P-gp induction can serve as a clinical therapeutic strategy by reducing the intracellular concentration of deleterious xenobiotics significantly, and the in silico P-gp induction pharmacophore model was also discussed. This review could be of great importance for pre-clinical drug design, the screening of new synthesized compounds and the prediction of potential clinical drug-drug interactions.
    • HTML全文
    • 参考文献(51)
  • [1] Silva R,Vilas-Boas V,Carmo H,et al.Modulation of P-glycoprotein efflux pump:induction and activation as a therapeutic strategy[J].Pharmacol Ther,2015,149:1-123.
    [2] Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier[J].Adv Drug Deliv Rev,1999,36(2/3):179-186.
    [3] Zhuo W,Hu L,Lv J,et al.Role of pregnane X receptor in chemotherapeutic treatment[J].Cancer Chemother Pharmacol,2014,74(2):217-227.
    [4] Hennessy M.A primer on themechanics of P-glycoprotein the multidrug transporter[J].Pharmacol Res,2007,55(1):1-15.
    [5] Weiss J,Theile D,Spalwisz A,et al.Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells[J].Biochem Pharmacol,2013,85(2):265-273.
    [6] Naruhashi K, Kurahashi Y, Fujita Y, et al. Comparison of the expression and function of ATP binding cassette transporters in Caco-2 and T84 cells on stimulation by selected endogenous compounds and xenobiotics[J].Drug Metab Pharmacok,2011,26(2):145-153.
    [7] Manceau S,Giraud C,Declèves X,et al.ABC drug transporter and nuclear receptor expression in human cytotrophoblasts:influence of spontaneous syncytialization and induction by glucocorticoids[J].Placenta,2012,33(11):927-932.
    [8] Haslam IS,Jones K,Coleman T,et al.Induction of P-glycoprotein expression and function in human intestinal epithelial cells(T84)[J].Biochem Pharmacol,2008,76(7):850-861.
    [9] Abuznait AH,Kaddoumi A.Role of ABC transporters in the pathogenesis of Alzheimer′s disease[J].ACS Chem Neurosci,2012,3(11):820-831.
    [10] He J, Tang J, Yang WH, et al. P-gp induction by curcumin:an effective antidotal pathway[J].J Bioequiv Bioavail, 2013,5(6):236-241.
    [11] Sérée E,Villard PH,Hevér A.Modulation of MDR1 and CYP3A expression by dexamethasone:evidence for an inverse regulation in adrenals[J].Biochem Biophys Res Commun,1998,252(2):392-395.
    [12] Wen T,Liu YC,Yang HW,et al.Effect of 21-day exposure of phenobarbital,carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain[J].J Neurol Sci,2008,271(1):99-106.
    [13] Foti RS.“Target-Site” drug metabolism and transport[J].Drug Metab Dispos,2015,43(8):1156-1168.
    [14] Müller F,Fromm MF.Transporter-mediated drug-drug interactions[J].Pharmacogenomics,2011,12(7):7-21.
    [15] Synold TW,Dussault I,Forman BM.The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux[J].Nat Med,2001,7(5):584-590.
    [16] Liu L,Collier AC,Link JM,et al.Modulation of P-glycoprotein at the human blood-brain barrier by quinidine or rifampin treatment:a positron emission tomography imaging study[J].Drug Metab Dispos,2015,43(11):1795-1804.
    [17] Sager JE,Yu J,Ragueneau-Majlessi I,et al.Physiologically based pharmacokinetic(PBPK)modeling and simulation approaches:a systematic review of published models,applications,and model verification[J].Drug Metab Dispos,2015,43(11):1823-1837.
    [18] Silva R,Carmo H,Dinis-Oliveira R,et al.In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells[J].Arch Toxicol,2011,85(4):315-326.
    [19] Silva R,Carmo H,Vilas-Boas V,et al.Colchicine effect on P-glycoprotein expression and activity:in silico and in vitro studies[J].Chem Biol Interact,2014,218:50-62.
    [20] Zerin T,Kim YS,Hong SY,et al.Protective effect of methylprednisolone on paraquat-induced A549 cell cytotoxicity via induction of efflux transporter,P-glycoprotein expression[J].Toxicol Lett,2012,208(2):101-107.
    [21] Silva R.Pglycoprotein induction in Caco 2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity[J].Arch Toxicol 2015,89:18.
    [22] Silva R,Sousa E,Carmo H,et al.Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat[J].Arch Toxicol,2014,88(4):937-951.
    [23] Fenner KS,Troutman MD,Kempshall S,et al.Drug-drug interactions mediated through P-glycoprotein:clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug[J].Clin Pharmacol Ther,2009,85(2):173-181.
    [24] Reitman ML,Chu X,Cai X,et al.Rifampin′s acute inhibitory and chronic inductive drug interactions:experimental and model-based approaches to drug-drug interaction trial design[J].Clin Pharmacol Ther,2011,89(2):234-242.
    [25] Fromm MF.Importance of P-glycoprotein at blood-tissue barriers[J].Trends Pharmacol Sci,2004,25(8):423-429.
    [26] Schwarz UI,Hanso H,Oertel R,et al.Induction of intestinal P-glycoprotein by St John′s wort reduces the oral bioavailability of talinolol[J].Clin Pharmacol Ther,2007,81(5):669-678.
    [27] Liu J,Zhou F,Chen Q,et al.Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-kappab pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis mice[J].Sci Rep,2015,5:13558.
    [28] Wen T,Liu YC,Yang HW,et al.Effect of 21-day exposure of phenobarbital,carbamazepine and phenytoin on P-glycoprotein expression and activity in the rat brain[J].J Neurol Sci,2008,270(1):99-106.
    [29] Jin S,Yao D,Liu C,et al.Effect of chronic liver failure on the function and expression of P-GP and MRP2 in rat brain[J].J China Pharm Univ(中国药科大学学报),2012,43(1):64-69.
    [30] Callaghan R,Luk F,Bebawy M.Inhibition of the multidrug resistance P-glycoprotein:time for a change of strategy[J]?Drug Metab Dispos,2014,42(4):623-631.
    [31] Albermann N, Schmitz-Winnenthal FH, Z′graggen K, et al.Expression of the drug transporters MDR1/ABCB1,MRP1/ABCC1,MRP2/ABCC2,BCRP/ABCG2,and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver[J].Biochem Pharmacol,2005,70(6):949-958.
    [32] Narang VS,Fraga C,Kumar N.Dexamethasone increases expresb>(4):694-705.
    [33] FDA. Guidance for industry, drug interaction studies-study design,data analysis,and implications for dosing and labeling recommendations[S].2012.J,Fuksa L,Brcakova E,et al.Up-regulation of renal Mdr1 and Mrp2 transporters during amiodarone pretreatment in rats[J].Pharmacol Res,2010,61(2):129-135.
    [34] Safa AR.Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators[J].Curr Med Chem Anticancer Agents,2004,4(1):1-17.
    [35] Aller SG, Yu J, Ward A.Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding[J].Science,2009,323(5922):1718-1722.
    [36] Drescher S,Glaeser H,Mürdter T,et al.P-glycoprotein mediated intestinal and biliary digoxin transport in humans[J].Clin Pharmacol Ther,2003,73(3):223-231.
    [37] Greiner B,Eichelbaum M,Fritz P,et al.The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin[J].J Clin Invest,1999,104(2):147-153.
    [38] Gurley BJ,Swain A,Williams DK,et al.Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions:comparative effects of St.John′s wort,Echinacea,clarithromycin,and rifampin on digoxin pharmacokinetics[J].Mol Nutr Food Res,2008,52(7):772-779.
    [39] Montanari F,Ecker GF.Prediction of drug-ABC-transporter interaction-Recent advances and future challenges[J].Adv Drug Deliv Rev,2015,86:17-26.
    [40] Westphal K,Weinbrenner A,Zschiesche M,et al.Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings:a new type of drug-drug interaction[J].Clin Pharmacol Ther,2000,68(4):345-355.
    [41] Schwarz UI,Hanso H,Oertel R.Induction of intestinal P-glycoprotein by St John′s wort reduces the oral bioavailability of talinolol[J].Clin Pharmacol Ther,2007,81(5):669-678.
    [42] Silva R.Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein[J].Arch Toxicol,2014,88(4):15.
    [43] Silva R,Palmeira A,Carmo H,et al.P-glycoprotein induction in Caco-2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity[J].Arch Toxicol,2015,89(10):1783-1800.
    [44] Dinis-Oliveira RJ, Remiao F, Duarte JA, et al. P-glycoprotein induction:an antidotal pathway for paraquat-induced lung toxicity[J].Free Radic Biol Med,2006,41(8):1213-1224.
    [45] Murgueitio MS,Bermudez M,Mortier J,et al.In silico virtual screening approaches for anti-viral drug discovery[J].Drug Discovery Today:Technologies,2012,9(3):e219-e225.
    [46] Lu JR,Wang FX,Li YM,et al.Synthesis,biological evaluation and 2D-QSAR study of a series of isoflavone derivatives as modulators of multidrug resistance[J].J China Pharm Univ(中国药科大学学报),2013,44(4):296-302.
    [47] Padala AK,Wani A,Vishwakarma RA,et al.Functional induction of P-glycoprotein efflux pump by phenyl benzenesulfonamides:synthesis and biological evaluation of T0901317 analogs[J].Eur J Med Chem,2016,122:744-755.
    [48] Vilas-Boas V,Silva R,Palmeira A.Development of novel rifampicin-derived P-glycoprotein activators/inducers.Synthesis,in silico analysis and application in the RBE4 cell model,using paraquat as substrate[J].PLoS One,2013,8(8):e74425.
    [49] Yamaura Y,Chapron BD,Wang Z,et al.Functional comparison of human colonic carcinoma cell lines and primary small intestinal epithelial cells for investigations of intestinal drug permeability and first-pass metabolism[J].Drug Metab Dispos,2016,44(3):329-335.
    [50] Bourgine J,Billaut-Laden I,Happillon M,et al.Gene expression profiling of systems involved in the metabolism and the disposition of xenobiotics:comparison between human intestinal biopsy samples and colon cell lines[J].Drug Metab Dispos,2012,40(4):694-705.
    [51] FDA. Guidance for industry, drug interaction studies-study design,data analysis,and implications for dosing and labeling recommendations[S].2012.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1672
  • HTML全文浏览量:  9
  • PDF下载量:  2171
  • 被引次数: 0
出版历程
  • 刊出日期:  2018-02-24

目录

摘要
HTML全文
    参考文献(51)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：336049

    x 关闭 永久关闭